Key result
Obese patients with type 2 diabetes had reduced insulin-stimulated blood flow compared to lean subjects.
Why the study?
Does obesity and type 2 diabetes alter skeletal muscle NO synthase and endothelin-1 expression and impair insulin-stimulated blood flow compared to lean insulin-sensitive individuals?
Observational (n=32)
Does obesity and type 2 diabetes alter skeletal muscle NO synthase and endothelin-1 expression and impair insulin-stimulated blood flow compared to lean insulin-sensitive individuals?
Higher basal skeletal muscle expression of ET-1 and reduced peNOS/eNOS may contribute to reduced insulin-stimulated blood flow in obese T2D patients.
Answers are grounded in this paper and cite their sources.
Reduced insulin-stimulated blood flow may reflect vascular insulin resistance in obese T2D; hypothesis-generating and requires validation in larger studies.
Increased endothelin-1 (ET-1) and reduced endothelial nitric oxide phosphorylation (peNOS) are hypothesized to reduce insulin-stimulated blood flow in type 2 diabetes (T2D), but studies examining these links in humans are limited. We sought to assess basal and insulin-stimulated endothelial signaling proteins (ET-1 and peNOS) in skeletal muscle from T2D patients. Ten obese T2D [glucose disposal rate (GDR): 6.6 ± 1.6 mg·kg lean body mass (LBM) −1 ·min −1 ] and 11 lean insulin-sensitive subjects (Lean GDR: 12.9 ± 1.2 mg·kg LBM −1 ·min −1 ) underwent a hyperinsulinemic-euglycemic clamp with vastus lateralis biopsies taken before and 60 min into the clamp. Basal biopsies were also taken in 11 medication-naïve, obese, non-T2D subjects. ET-1, peNOS (Ser1177), and eNOS protein and mRNA were measured from skeletal muscle samples containing native microvessels. Femoral artery blood flow was assessed by duplex Doppler ultrasound. Insulin-stimulated blood flow was reduced in obese T2D (Lean: +50.7 ± 6.5% baseline, T2D: +20.8 ± 5.2% baseline, P < 0.05). peNOS/eNOS content was higher in Lean under basal conditions and, although not increased by insulin, remained higher in Lean during the insulin clamp than in obese T2D ( P < 0.05). ET-1 mRNA and peptide were 2.25 ± 0.50- and 1.52 ± 0.11-fold higher in obese T2D compared with Lean at baseline, and ET-1 peptide remained 2.02 ± 1.9-fold elevated in obese T2D after insulin infusion ( P < 0.05) but did not increase with insulin in either group ( P > 0.05). Obese non-T2D subjects tended to also display elevated basal ET-1 ( P = 0.06). In summary, higher basal skeletal muscle expression of ET-1 and reduced peNOS/eNOS may contribute to a reduced insulin-stimulated leg blood flow response in obese T2D patients. NEW & NOTEWORTHY Although impairments in endothelial signaling are hypothesized to reduce insulin-stimulated blood flow in type 2 diabetes (T2D), human studies examining these links are limited. We provide the first measures of nitric oxide synthase and endothelin-1 expression from skeletal muscle tissue containing native microvessels in individuals with and without T2D before and during insulin stimulation. Higher basal skeletal muscle expression of endothelin-1 and reduced endothelial nitric oxide phosphorylation (peNOS)/eNOS may contribute to reduced insulin-stimulated blood flow in obese T2D patients.
No takes yet. Share an insight, caveat, or question.
Reynolds et al. (2016) conducted an observational in Type 2 diabetes and obesity (n=32). Obesity and Type 2 Diabetes vs. Lean insulin-sensitive subjects was evaluated on Insulin-stimulated blood flow (% increase from baseline) (p=<0.05). Obese patients with type 2 diabetes had reduced insulin-stimulated blood flow compared to lean subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: